Every material Form 8-K Imunon, Inc. has filed with the SEC since September 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Imunon, Inc. made an investor presentation available on October 26, 2026, which it expects to use in investor calls and conferences. The filing attaches the presentation as Exhibit 99.1 and contains no new financial results, guidance, or transaction terms.
Investor presentation made available October 26, 2026, titled "Imunon, Inc. Investor Presentation October 2026"
Company expects to use the presentation in investor calls and/or conferences
Filing includes no financial figures, guidance, or deal terms in the 8-K text
On October 20, 2026, Imunon agreed to sell its ThermoDox assets to VoxelDox Therapeutics. The deal closes only if VoxelDox raises at least $2.5 million; otherwise Imunon receives no consideration, and if it closes, Imunon would receive a 4.76% equity stake, up to $16.5 million in milestone payments, and royalties on net sales. The company describes ThermoDox as a legacy asset that has been fully written off and says it will keep its resources focused on the IMNN-001 Phase 3 program.
Closing depends on VoxelDox raising at least $2.5 million; no consideration is paid if it does not.
If the deal closes, Imunon receives 4.76% of VoxelDox's fully diluted capitalization.
Imunon could receive up to $16.5 million in milestone payments and royalties on annual net sales; milestones and royalties are cut by 50% if the transferred vials are determined to be unusable.
Imunon may appoint one of VoxelDox's five directors and one non-voting observer until VoxelDox completes a qualified equity financing.
Imunon, Inc. agreed on September 28, 2026 to exchange $1,200,000 of principal on its A-1 secured note held by Streeterville Capital, LLC for 120 shares of newly designated Series B Preferred Stock, reducing the note balance by the amount exchanged. The company also filed a certificate of designation creating 200 Series B shares with an 8% annual return and a 110% optional redemption price, which carries event-of-default terms that could raise the return by 15% a year.
Exchange covers $1,200,000 of A-1 Note principal plus accrued interest, for 120 Series B Preferred Shares at $10,000 per share.
Series B Preferred Stock has a $12,000 stated value, an 8% annual return, and is not convertible into common stock.
Company may redeem Series B shares at 110% of the applicable liquidation amount; an event of default would raise the return by 15% per year.
Series B holders have no voting rights except on matters that materially and adversely affect their rights or as required by law.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Imunon, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →